Anti-Human CD279 (PD-1) (Nivolumab) - PE
Code | Size | Price |
---|
LEI-LT1204-50ug | 50 ug | £265.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Human
Antibody Isotype: Human IgG1κ
Antibody Clonality: Monoclonal
Antibody Clone: 5C4.B8
Regulatory Status: RUO
Target Species:
- Cynomolgus Monkey
- Human
Applications:
- Flow Cytometry
- Functional Study
- Immunohistochemistry (IHC)
Shipping:
2-8°C
Storage:
This R-phycoerythrin (R-PE) conjugate is stable when stored at 2-8°C. Do not freeze.
Further Information
Antigen Distribution:
PD-1 is expressed on a subset of CD4-CD8- thymocytes, and on activated T and B cells.
Concentration:
0.2 mg/ml
Conjugate/Tag/Label:
R-phycoerythrin (PE)
Format:
This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
Human PD-1
Long Description:
Programmed cell death protein 1 (PD-1) is a protein on the surface of cells that plays a role in the maintenance of self-tolerance. PD-1 promotes self-tolerance via the down-regulation of the immune system which results in the suppression of T cell inflammatory activity. PD-L1 and PD-L2 are the two ligands known to bind PD-1. PD-L1 has increased expression in several cancers.1 PD-L2 has a more limited expression and is primarily expressed by dendritic cells and only some tumor lines. Inhibition of the interaction of PD-1 with its ligands can function as an immune checkpoint blockade through the improvement of In vitro T-cell responses and via the mediation of anti-tumor activity.2 Nivolumab disrupts the negative signal that is responsible for T-cell activation and proliferation by binding to PD-1 on activated immune cells to selectively block the interaction of the PD-1 receptor with its ligands.3 Emerging research suggests that combined blockade of PD-1 and CTLA-4, with nivolumab and ipilimumab respectively, could produce greater antitumor activity than blockade of either pathway alone.4 This cost-effective, research-grade Anti-Human CD279 (PD-1) (Nivolumab) utilizes the same variable regions from the therapeutic antibody Nivolumab making it ideal for research projects.
NCBI Gene:
5133
Target:
PD-1
References
1. Minato, N. et al. (2002) Proc Natl Acad Sci U S A. 99(19): 12293?97.
2. Korman, AJ. et al. (2014) Cancer Immunol Res. 2(9):846-56.
3. Li, Y. et al. (2016) MAbs. 8(5):951-60.
4. Wolchok, JD. et al. (2013) N Engl J Med 369(2):122-33.